
        <!DOCTYPE html>
        <html>
        <head>
            <title>Catalyst Pharmaceuticals Inc. (CPRX) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Catalyst Pharmaceuticals Inc. (CPRX)</h1>
                    <a href="index.html" class="back-btn">‚Üê Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">21</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">9</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">2</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.15</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=29a444a2fc03cf2a20e91bda82185af5df4aca1e85b8d54794e66c6b2d2fb149" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceuticals, Inc. (CPRX) Secures FIRDAPSE Market Exclusivity Until 2035</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-29</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Catalyst Pharmaceuticals, Inc. is placed sixth among them. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8d2c7329bf5d8718d9721e61d8d3580b1c474b38e840616a73f75fea2bfc867b" target="_blank" rel="noopener noreferrer">Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-29</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f087a6c6a6d6cfcabdcfb810056bf11ae98ef58c69a306cd2f63c8e75ef7e9b4" target="_blank" rel="noopener noreferrer">Tracking Terry Smith's Fundsmith 13F Portfolio - Q2 2025 Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-28</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Read here for an in-depth analysis and insights on Fundsmith's $23.02B portfolio shift: new stakes, exits, and top positions like Meta and Microsoft....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=a9d55c873aba3112f1c0a12c922567b11ba48a42832adf99d8499066cf68a7ad" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-28</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7ae045cf4522fe56f343feb0a578396630527ed89bb34a7b8dccfe3c6a639681" target="_blank" rel="noopener noreferrer">UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE¬Æ (amifampridine) Patent Litigation with Lupin Pharmaceuticals</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-27</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.24
                                </span>
                            </div>
                            <div class="article-summary">As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (‚ÄúCatalyst...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=631f98c7e8fe907250900b24455342926bd4f13d59bb5aed4dfff658a64e8f99" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-26</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.30
                                </span>
                            </div>
                            <div class="article-summary">CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=24b34e5f89175bd4436d9c3c4a58c4dd0b589c66aed8af4b26fd4e1cff97b880" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE¬Æ (amifampridine) Patent Litigation with Lupin Pharmaceuticals</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.32
                                </span>
                            </div>
                            <div class="article-summary">As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c3907d374789a13bcc0a4f263b16cfc191ed507efec252bde9661f419a70bf5a" target="_blank" rel="noopener noreferrer">Pharmaceuticals Industry Analysis:¬† Eli Lilly Tops My Tier Two</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-20</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.36
                                </span>
                            </div>
                            <div class="article-summary">Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for an analysis....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=11145c64541d120cedc50f9e05e375f278555b760f549393511866981f4baaa5" target="_blank" rel="noopener noreferrer">Macquarie Small Cap Growth Fund Q2 2025 Commentary</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-19</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">For 2Q25, Macquarie Small Cap Growth Fund Institutional Class shares outperformed the Fund√¢¬Ä¬ôs benchmark, the Russell 2000 Growth Index. Read more here....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=990dc6555970a1d3f9b5fe6036737ee90fa0e09c16016c0afd4c812274041dd0" target="_blank" rel="noopener noreferrer">Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-15</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.24
                                </span>
                            </div>
                            <div class="article-summary">Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9e692c4dd8b418bbf42c557d324bb79e518148bbd389297feaf8be64f1fd7090" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-13</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.42
                                </span>
                            </div>
                            <div class="article-summary">NasdaqCM:CPRX 1 Year Share Price vs Fair Value Explore Catalyst Pharmaceuticals's Fair Values from the Community and......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=fccfc4371b091c07c735848ea3c527ca3fb119fb032707394eeaeee22dff84d0" target="_blank" rel="noopener noreferrer">Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-13</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=370aa5d258afc0d5bf20bde7587793f433f79edc7e262850aa869185db1cc49d" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceuticals: A Developing Story That's Cheap Enough</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-12</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.30
                                </span>
                            </div>
                            <div class="article-summary">Catalyst Pharmaceuticals stock shines with FIRDAPSE & AGAMREE growth. Learn why the biopharma name is cheap enough to start accumulating....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6322a768e0035be4c588b645ae2ad22f4d8bd8fb40eae5febfc9a1446972c047" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.36
                                </span>
                            </div>
                            <div class="article-summary">Catalyst (CPRX) delivered earnings and revenue surprises of +17.24% and +5.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=0033f8b364192e25545af819f2b4c8e002b9ba0bbf88b715ff536167704858aa" target="_blank" rel="noopener noreferrer">Catalyst (CPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare t...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=abf2d60a2a236d6649b4007a06045223814f1a83fd60418bf1606014059ba536" target="_blank" rel="noopener noreferrer">Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=28dcff8690461dd485b5a77edc89f00cdcb30bf82da42cacc50842e21dc5d82f" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.95
                                </span>
                            </div>
                            <div class="article-summary">CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c53c18dd0b25d7044eb44d8cd3a805374ea011d20b81c16d238c1abeffd03708" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ETCompany ParticipantsJeffrey Del Carmen - Executive VP......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=73e8fa6b2f224ea7c348095b5c400ee9960260661828ed0ca90222e5c26705d5" target="_blank" rel="noopener noreferrer">Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of can...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c730701980048a827912de7b2fd76ffbe8f7f04206eed14eab144e758bafc5e2" target="_blank" rel="noopener noreferrer">Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.57
                                </span>
                            </div>
                            <div class="article-summary">Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an I...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=b61b9f5e62aaa2a4361f7b9eb3ce136af224dae6eec37cd496832df36c16af83" target="_blank" rel="noopener noreferrer">Catalyst: Q2 Earnings Snapshot</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.24
                                </span>
                            </div>
                            <div class="article-summary">On a per-share basis, the Coral Gables, Florida-based company said it had profit of 41 cents. Earnings, adjusted for pretax expenses and amortization costs, were 68 cents per share. The results beat W...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        